Stockscreener 앱 받기
145.46
1.32%
1.89
시간 외 거래:
146.00
0.54
+0.37%
Novartis Ag Adr 주식(NVS)의 최신 뉴스
Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight - GlobeNewswire Inc.
Novartis stock gains 0.62 percent at the close - AD HOC NEWS
Novartis stock ends the day at USD 141.43 after the close - AD HOC NEWS
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis stock holds steady as investors weigh recent results and pipeline outlook - AD HOC NEWS
Novartis AGADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Novartis stock recovers after trial setbacks as analysts lift earnings outlook - AD HOC NEWS
Novartis stock stabilizes after trial setbacks as investor pushes for board shake-up - ad-hoc-news.de
Sarepta Therapeutics Inc Share PriceSRPT, RNS News, Articles, Quotes, & Charts (NASDAQ:SRPT) - Proactive financial news
NVS Stock Quote Price and Forecast - CNN
Why Did Novartis (NYSE:NVS) Shares React to Study Results? - Kalkine Media
US markets today: Dow, S&P 500, Nasdaq futures indicate negative open, PPI data in focus; Apple, Novartis, others to watch - Upstox
HSBC upgrades Novartis stock rating to hold on pipeline clarity - Investing.com
Novartis' Strong Innovation Supports Industry-Leading Margins - Morningstar
Dow closes sharply lower as oil surge fuels inflation fears - Proactive financial news
Dow slides as oil nears $100, US-Canada trade tensions escalate - Proactive financial news
Amgen Stock Eyes Worst Day Since 2000 on Novartis Lp(a) FailureAmgen (NASDAQ:AMGN) - benzinga.com
Novartis stock falls sharply after third late-stage trial failure in a week - ad-hoc-news.de
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial - finance.yahoo.com
Market movers: Novartis, Qualcomm, EchoStar, BioVie... - proactiveinvestors.com.au
Novartis Down Over 12%, On Pace for Record Percent Decrease -- Data Talk - Moomoo
Dow Jones, S&P 500 futures indicate gap-down open while Nasdaq set for flat start; Novartis, Amgen, others to watch - Upstox
Novartis initiates phase 2 study of MRT-6160 for Sjögren’s disease - Investing.com Nigeria
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Novartis shares fall after second major trial setback in days - The Globe and Mail
Novartis shares plunge 10% as failed drug trial clouds growth outlook - Investing.com Nigeria
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Why is Novartis stock sliding today? - Investing.com
Novartis shares fall after heart drug fails late-stage trial - in.investing.com
Novartis shares fall after heart drug fails late-stage trial By Investing.com - Investing.com Canada
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Novartis stock slips as Jefferies and UBS stay neutral after Hybrozyme deal - ad-hoc-news.de
Novartis stock gains as remibrutinib data and Fabhalta growth offset cell therapy trial pause - ad-hoc-news.de
Novartis Up 5.6% After MS Pill Gains $3 Billion Sales Potential - ts2.tech
Novartis stock gains as remibrutinib MS data offsets CAR T trial pause - AD HOC NEWS
Why Is Novartis Stock Soaring Tuesday?Novartis (NYSE:NVS) - Benzinga
Novartis remibrutinib cuts MS relapse rates in Phase 3 - grafa.com
US markets today: Dow, S&P 500, Nasdaq futures indicate gap-down open; Novartis, Duolingo, energy stocks to watch - Upstox
Novartis shares rise after multiple sclerosis drug hits late-stage trial goals - Investing.com Australia
Novartis stock steadies after pause of autoimmune cell therapy trials - AD HOC NEWS
Novartis stock trades mixed as investors weigh post-earnings outlook - ad-hoc-news.de
Novartis stock trades below consensus target as post-earnings digestion continues - AD HOC NEWS
Novartis stock holds steady as investors digest latest 2026 earnings and guidance - AD HOC NEWS
Novartis stock holds steady as oncology and Alzheimer’s pipeline draws attention - ad-hoc-news.de
1.23%
자본화:
|
볼륨(24시간):